Cerus CERS
- Market cap
- $475.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $233.4M
- +14% on a year ago
- Net margin
- −2.9%
- Free cash flow yield
- −0.4%
Cerus trades at 2.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $233.4M over the last twelve months, up 14% on a year earlier with a −3% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $53.3M+4% | $43.4M+13% | $50.5M+6% | $50.7M+7% | $56.8M+6% | $43.2M−0% | $52.4M+4% | $52.7M+4% | $64.6M+14% | $53.7M+24% | $57.4M+10% | $57.7M+10% | |
| Cost of revenue | $20.8M+7% | $17.1M+25% | $20.4M+17% | $19.8M+10% | $23.4M+13% | $17.8M+4% | $23.5M+15% | $24.6M+24% | $28M+20% | $25.8M+45% | $27.9M+19% | $27.4M+12% |
| Gross profit | $26M+6% | $21.3M+23% | $24.7M+16% | $26.2M+20% | $27.4M+6% | $25.4M+20% | $29M+18% | $28.1M+7% | $29.7M+9% | $27.9M+10% | $29.5M+2% | $30.3M+8% |
| R&D | $14.3M−23% | $14.5M−17% | $15M−22% | $14M−17% | $15.4M+8% | $16.6M+15% | $18.9M+26% | $15.8M+13% | $16.4M+6% | $14.5M−13% | $14.4M−24% | $14.3M−10% |
| SG&A | $17.3M−25% | $19.8M−8% | $19M−8% | $17.8M+10% | $19.3M+12% | $20.3M+3% | $21.2M+12% | $18.6M+5% | $20.8M+8% | $19.9M−2% | $22.9M+8% | $21.9M+18% |
| $976K | −$8M−44% | −$3.8M−67% | −$961K−82% | −$1.4M | −$5.9M−27% | −$3.4M−11% | $1.2M | −$641K−56% | −$354K−94% | −$1.9M−46% | $383K−69% | |
| Interest expense | $2.2M+31% | $2.2M+39% | $2.3M+7% | $2.3M−4% | $2.1M−8% | $2.1M−6% | $2.1M−8% | $2.1M−6% | $2M−4% | $1.9M−11% | $1.7M−20% | $1.2M−42% |
| Pre-tax income | −$1.3M−90% | −$9.6M−38% | −$5.8M−56% | −$2.9M−60% | −$2.5M+86% | −$7.6M−21% | −$5.6M−3% | $65K | −$2.1M−16% | −$1.6M−80% | −$2.9M−49% | −$514K |
| $72K−73% | $74K−4% | −$56K | $76K−3% | $111K+54% | $74K+0% | $76K | $85K+12% | $119K+7% | $91K+23% | $95K+25% | $66K−22% | |
| Net income | −$1.3M−90% | −$9.7M−38% | −$5.8M−57% | −$2.9M−60% | −$2.5M+90% | −$7.7M−20% | −$5.7M−1% | −$19K−99% | −$2.2M−13% | −$1.6M−79% | −$2.9M−49% | −$550K+2795% |
| −$0.01−88% | −$0.05−44% | −$0.03−57% | −$0.02−50% | −$0.01+0% | −$0.04−20% | −$0.03+0% | $0.00 | −$0.01+0% | −$0.01−75% | −$0.01−67% | $0.00 | |
| 181.2M+2% | 182.1M+2% | 185M+2% | 185.4M+3% | 185.7M+3% | 187.1M+3% | 191.3M+3% | 191.8M+4% | 192.1M+3% | 194.1M+4% | 200.6M+5% | 201.7M+5% |
EPS, diluted: 9 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Cerus' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CERSCerus | $475.6M | n/m | n/a | 2.0× | +14% | −2.9% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| Peer median | $614.5M | 21.3× | 34.3× | 1.9× | +5% | 7.8% |
Investors who own it
Investors we follow who held Cerus at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management0.3% of portfoliotrimmed
More on Cerus
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .